HAENYSESurgical & Medical Instruments & ApparatusFiscal year ends April 3

HAEMONETICS CORP

Financials through Q1 FY2027, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 6, 2026

$118.73+0.45 (+0.38%)

Close on Oct 19, 2026

Market cap: $5.43B
P/E (TTM): 57.9
Dividend yield: –

Dividends

Haemonetics has not reported a dividend

No dividend per share appears in Haemonetics's annual filings since fiscal 2011.

Where these numbers come from

Parsed from the XBRL in Haemonetics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Dec 3, 2012
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is HAE.

Revenue growth0.4% · median 10.2%

Gross margin59.0% · median 52.5%

Operating margin11.9% · median 4.0%

Net margin7.1% · median 1.4%

Company	Revenue	Growth
TFX	$2.25B	+30.7%
ICUI	$2.16B	-9.0%
IART	$1.65B	+1.6%
MMSI	$1.58B	+10.2%
PEN	$1.50B	+17.6%
HAE	$1.35B	+0.4%

Company

Next earnings (est.): Nov 5, 2026, before open
Exchange: NYSE
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: April 3
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 313143

Advertisement
300 × 250